Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis

Disease Markers

Volumn 27, Issue 2, 2009, Pages 63-73

  Achiron, Anat ^a,b   Feldman, Anna ^a,b   Gurevich, Michael ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Gene expression; Glatiramer acetate; Immune modulation; Markers; Multiple sclerosis

Indexed keywords

GLATIRAMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFECT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; APOPTOSIS; BIOLOGICAL MARKERS; CELL ADHESION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 74049156448     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/267581     Document Type: Article

References (48)

1. L. Steinman, R. Martin, C. Bernard, P. Conlon and J.R. Oksenberg, Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy, Annu Rev Neurosci 25 (2002), 491-505.
2. B. Hemmer, S. Cepok, S. Nessler and N. Sommer, Pathogenesis of multiple sclerosis: an update on immunology, Curr Opin Neurol 15 (2002), 227-231.
3. J.S.Wolinsky, Glatiramer acetate for the treatment of multiple sclerosis, Expert, Opin Pharmacother 5 (2004), 875-891.
4. F. Martinelli Boneschi, M. Rovaris, K.P. Johnson, A. Miller, J.S. Wolinsky, D. Ladkani G. Sheroni C. Giancarlo and F. Massimo, Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo controlled clinical trials, Mult Scler 9 (2003), 349-355.
5. R. Arnon and R. Aharoni, Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications, Proc Natl Acad Sci USA, 101(Suppl 2) (2004), 14593-14598.
6. R. Arnon and R. Aharoni, Neurogenesis and neuroprotection in the CNS-fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders, Mol Neurobiol 36 (2007), 245-253.
7. R. Aharoni, A. Herschkovitz, R. Eilam, M. Blumberg-Hazan, M. Sela, W. Bruck and R. Arnon, Proc Natl Acad Sci USA 12 (2008), 11358-11363.
8. J.M. Scorisa, R.G. Zanon, C.M. Freria and A.L. de Oliveira, Glatiramer acetate positively influences spinal motoneuron survival and synaptic plasticity after ventral root avulsion, Neurosci Lett 451 (2009), 34-39.
9. E.C. Wang, A. Thern, A. Denzel, J. Kitson, S.N. Farrow and M.J. Owen, DR3 Regulates negative selection during thymocyte development, Mol Cell Biol 21 (2001), 3451-3461.
10. H. Zhao, M. Yan, H.Wang, S. Erickson, I.S. Grewal and V.M. Dixit, Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice, J Exp Med 194 (2001), 1441-1448.
11. A.M. Siwkowski, L.A. Madge, S. Koo, E.L. McMillan, B.P. Monia, J.S. Pober and B.F. Baker, Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNFinduced gene expression, Mol Pharmacol 66 (2004), 572-579.
12. A.M. Al-Zoubi, E.V. Efimova, S. Kaithamana, O. Martinez, El-Idrissi Mel-A, R.E. Dogan and B.S. Prabhakar, Contrasting Effects of IG20 and its Splice Isoforms, MADD and DENNSV, on Tumor Necrosis Factor α-induced Apoptosis and Activation of Caspase-8 and -3, J Biol Chem 276 (2001), 47202-47211.
13. J.H. Lee, S.B. Rho and T. Chun, Programmed cell death 6 (PDCD6) protein interacts with death-associated protein kinase1( DAPk1): additive effect on apoptosis via caspase-3 dependent pathway, Biotechnol Lett 27 (2005), 1011-1015.
14. C. Pop, J. Timmer, S. Sperandio and G.S. Salvesen, The apoptosome activates caspase-9 by dimerization, Mol Cell 22 (2006), 269-275.
15. N. Inohara, T. Koseki, L. del Peso, Y. Hu, C. Yee, S. Chen, R. Carrio, J. Merino, D. Liu, J. Ni, and G. Ńũnez, Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappa-B, J Biol Chem 274 (1999), 14560-14567.
16. I. Pitha-Rowe, W.J. Petty, Q. Feng, P.H. Koza-Taylor, D.A. Dimattia, L. Pinder, K.H. Dragnev, N. Memoli, V. Memoli, T. Turi, J. Beebe, S. Kitareewan and E. Dmitrovsky, Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention, Cancer Res 64 (2004), 8109-8115.
17. P. Behrens, U. Brinkmann and A.Wellmann, CSE1L/CAS: Its role in proliferation and apoptosis, Apoptosis 8 (2003), 39-44.
18. S. Yoshimura, K. Yoshioka, F.A. Barr, M. Lowe, K. Nakayama, S. Ohkuma and N. Nakamura, Convergence of cell cycle regulation and growth factor signals on GRASP65, J Biol Chem 280 (2005), 23048-23056.
19. R.J. Allcock, J.H. Williams and P. Price, The central MHC gene, BAT1, may encode a protein that down-regulates cytokine production, Genes Cells 6 (2001), 487-494.
20. T.M. Williams, G. Montoya, Y. Wu, R.L. Eddy, M.G. Byers and T.B. Shows, The TCF8 gene encoding a zinc finger protein (Nil-2-a) resides on human chromosome 10p11.2, Genomics 14 (1992), 194-196.
21. R. Starr, T.A. Willson, E.M. Viney, L.J. Murray, J.R. Rayner, B.J. Jenkins T.J. Gonda, W.S. Alexander, D. Metcalf, N.A. Nicola and D.J. Hilton, A family of cytokine-inducible inhibitors of signalling, Nature 387 (1997) 917-921.
22. U. Schonbeck and P. Libby, The CD40/CD154 receptor/ligand dyad, Cell Mol Life Sci 58 (2001), 4-43.
23. R. De Caterinam and A. Zampolli, From asthma to atherosclerosis- 5-lipoxygenase, leukotrienes, and inflammation, New Eng J Med 350 (2004), 4-7.
24. M.T. Damiani, M. Pavarotti, N. Leiva, A.J. Lindsay, M.W. McCaffrey and M.I. Colombo, Rab coupling protein associates with phagosomes and regulates recycling from the phagosomal compartment, Traffic 5 (2004), 785-797.
25. S.N. Maiti, K. Balasubramanian, J.A. Ramoth and A.J. Schroit. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members, J Biol Chem 283 (2008), 3761-3766.
26. R.W. Wilson, C.M. Ballantyne, C.W. Smith, C. Montgomery, A. Bradley,W.E. O'Brien, A.L. Beaudet, Gene targeting yields a CD18-mutant mouse for study of inflammation, J Immunol 151 (1993), 1571-1578.
27. M.A. Arnaout, S.K. Gupta, M.W. Pierce and D.G. Tenen, Amino acid sequence of the alpha subunit of human leukocyte adhesion receptor Mo1 (complement receptor type 3), J Cell Biol 106 (1988), 2153-2158.
28. S. Ishii, T. Nagase and T. Shimizu, Platelet-activating factor receptor, Prostaglandins Other Lipid Mediat 68-69 (2002), 599-609. (Pubitemid 35247423)
29. M. Pignatelli. Integrins, cadherins, and catenins: molecular cross-talk in cancer cells, J Pathol 186 (1998), 1-2.
30. T.L. Gumienny, E. Brugnera, A.C. Tosello-Trampont, J.M. Kinchen, L.B. Haney, K. Nishiwaki, S. Walk, M. Nemergut, I. Macara and R. Franci, CED-12/ELMO, a novel member of the CrkII/Dock180/Rac pathway, is required for phagocytosis and cell migration, Cell 107 (2001), 27-41.
31. D. Kioussis andW. Ellmeier, Chromatin and CD4, CD8A and CD8B gene expression during thymic differentiation, Nat Rev Immunol 2 (2002), 909-919.
32. K.S. Boles, W. Barchet, T. Diacovo, M. Cella and M. Colonna, The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM, Blood 106 (2005), 779-786.
33. Z. Trachtulec, C. Vlcek, O. Mihola and J. Forejt, Comparative analysis of the PDCD2-TBP-PSMB1 region in vertebrates, Gene 335 (2004), 151-157.
34. M.P. Martin, X. Gao, J.H. Lee, G.W. Nelson, R. Detels, J.J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, M.Wilson, S.J. O'Brien and M. Carrington, Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS, Nat Genet 31 (2002), 429-434.
35. Y.K. Semra, O.A. Seidi and M.K. Sharief, Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis, J Neuroimmunol 113 (2001), 268-274.
36. B.M. Brinkman, J.B. Telliez, A.R. Schievella, L.L. Lin and A.E. Goldfeld, Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression, J Biol Chem 274 (1999), 30882-30886.
37. M. Ruggieri, C. Avolio, S. Scacco, C. Pica, A. Lia, G.B. Zimatore, S. Papa, P. Livrea and M. Trojano, Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients, J Neurol 253 (2006), 231-236.
38. M. Rieks, V. Hoffmann, O. Aktas, M. Juschka, I. Spitzer, N. Brune, S. Schimrigk, H. Przuntek and D. Pöhlau, Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate, Eur Neurol 50 (2003), 200-206.
39. M. Chen, B. Gran, K. Costello, K. Johnson, R. Martin and S. Dhib-Jalbut, Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS, Mult Scler 7 (2001), 209-219.
40. A.G. Eliopoulos, M. Stack, C.W. Dawson, K.M. Kaye, L. Hodgkin, S. Sihota, M. Rowe and L.S. Young, Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors, Oncogene 14 (1997), 2899-2916.
41. I.D. Dimitriou, L. Clemenza, A.J. Scotter, G. Chen, F.M. Guerra and R. Rottapel, Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1and SOCS3 proteins, Immunol Rev 224 (2008), 265-283.
42. R. Balabanov, K. Strand, A. Kemper, J.Y. Lee and B. Popko, Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-gamma, J Neurosci 26 (2006), 5143-5152.
43. K. Gerritse, J.D. Laman, R.J. Noelle, J.A. Ledbetter, W.J Boersma and E. Claassen, CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc Natl Acad Sci USA 93 (1996), 2499-2504.
44. A. Ben-Nun, I. Mendel, R. Bakimer, M. Fridkis-Hareli, D. Teitelbaum, R. Arnon, M. Sela and N. Kerlero de Rosbo, The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease, J Neurol 243(4 Suppl 1), (1996), S14-S22.
45. N.J. Karandikar, M.P. Crawford, X. Yan, R.B. Ratts, J.M. Brenchley, D.R. Ambrozak, A.E. Lovett-Racke, E.M. Frohman, P. Stastny, D.C. Douek, R.A Koup and M.K Racke, Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis, J Clin Invest 109 (2002), 641-649.
46. A.J. Johnson, G.L. Suidan, J. McDole and I. Pirko, The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? Int Rev Neurobiol 79 (2007), 73-97.
47. L. Airas, M. Saraste, S. Rinta, I. Elovaara, Y.H. Huang and H. Wiendl, Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells, Clin Exp Immunol 151 (2008), 235-243.
48. A. Horani, N. Muhanna, O. Pappo, A. Melhem, C.E. Alvarez, S.W.Wehbi, K. Dimitrios, S.L. Friedman and R. Safadi, Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis, Am J Physiol Gastrointest Liver Physiol 292 (2007), G628-G638.